S. Mushtaq

发表

A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus.

D. Livermore, S. Neidle, M. Gunaratnam, 2013, International journal of antimicrobial agents.

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

N. Woodford, D. Livermore, D. Paterson, 2010, The Lancet. Infectious diseases.

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D &bgr;-lactamases

N. Woodford, D. Livermore, S. Mushtaq, 2017, The Journal of antimicrobial chemotherapy.

Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases.

N. Woodford, D. Livermore, R. Pike, 2011, The Journal of antimicrobial chemotherapy.

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.

N. Woodford, D. Livermore, G. Hasçelik, 2008, International journal of antimicrobial agents.

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.

D. Livermore, S. Mushtaq, C. Horner, 2019, The Journal of antimicrobial chemotherapy.

New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.

N. Woodford, D. Livermore, M. Doumith, 2016, The Journal of antimicrobial chemotherapy.

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.

D. Livermore, S. Mushtaq, Yigong Ge, 2010, The Journal of antimicrobial chemotherapy.

Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants

N. Woodford, D. Livermore, M. Warner, 2015, Antimicrobial Agents and Chemotherapy.

Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.

N. Woodford, D. Livermore, M. Warner, 2015, The Journal of antimicrobial chemotherapy.

Inherent colistin resistance in Genogroups of the Enterobacter cloacae complex: 1 epidemiological, genetic and biochemical analysis from the BSAC Resistance

Rachael, Chaudhry, M. C. Gilmore, 2020 .

Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential

D. Livermore, S. Mushtaq, Yigong Ge, 2004, Antimicrobial Agents and Chemotherapy.

Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.

N. Woodford, D. Livermore, A. Kearns, 2015, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

D. Livermore, M. Warner, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.

N. Woodford, D. Livermore, M. Ellington, 2020, The Journal of antimicrobial chemotherapy.

Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK)

N. Woodford, F. Davies, H. H. Wu, 2018, The Journal of antimicrobial chemotherapy.

In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

N. Woodford, D. Livermore, M. Warner, 2015, Antimicrobial Agents and Chemotherapy.

Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias

N. Woodford, D. Livermore, R. Reynolds, 2021, JAC-antimicrobial resistance.

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.

D. Livermore, A. Johnson, M. Warner, 2004, International journal of antimicrobial agents.

Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.

D. Livermore, M. Warner, S. Mushtaq, 2005, The Journal of antimicrobial chemotherapy.

Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.

D. Livermore, D. James, M. Warner, 2010, The Journal of antimicrobial chemotherapy.

Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.

D. Livermore, D. James, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

Performance of the Oxoid M.I.C.Evaluator™ Strips compared with the Etest® assay and BSAC agar dilution

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.

N. Woodford, D. Livermore, S. Mushtaq, 2021, The Journal of antimicrobial chemotherapy.

Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles

N. Woodford, D. Livermore, K. Hopkins, 2017, The Journal of antimicrobial chemotherapy.

Evaluation of temocillin for phenotypic carbapenemase screening of Escherichia coli and Salmonella enterica isolates in relation to the presence of genes encoding ESBLs and carbapenemase production

H. Hasman, N. Woodford, R. Hendriksen, 2018, The Journal of antimicrobial chemotherapy.

Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis.

N. Woodford, D. Livermore, S. Hopkins, 2011, The Journal of antimicrobial chemotherapy.

Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria.

N. Woodford, D. Livermore, M. Warner, 2014, The Journal of antimicrobial chemotherapy.

Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.

D. Livermore, M. Warner, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms.

D. Livermore, M. Warner, S. Mushtaq, 2009, The Journal of antimicrobial chemotherapy.

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

N. Woodford, D. Livermore, M. Warner, 2012, The Journal of antimicrobial chemotherapy.

Evaluation of the chromogenic Cica-β-Test for detecting extended-spectrum, AmpC and metallo-β-lactamases

D. Livermore, M. Warner, S. Mushtaq, 2007 .

Evaluation of the chromogenic Cica-beta-Test for detecting extended-spectrum, AmpC and metallo-beta-lactamases.

D. Livermore, M. Warner, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

N. Woodford, D. Livermore, M. Warner, 2016, Antimicrobial Agents and Chemotherapy.

Inactivation or inhibition of AcrAB-TolC increases resistance of carbapenemase-producing Enterobacteriaceae to carbapenems.

N. Woodford, L. Piddock, M. Webber, 2016, The Journal of antimicrobial chemotherapy.

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

N. Woodford, D. Livermore, M. Warner, 2017, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

N. Woodford, D. Livermore, S. Mushtaq, 2020, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceﬁderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

D. Livermore, S. Mushtaq, A. Vickers, 2020 .

Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.

D. Livermore, S. Mushtaq, 2013, The Journal of antimicrobial chemotherapy.

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae

N. Woodford, D. Livermore, M. Warner, 2010, Antimicrobial Agents and Chemotherapy.

Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales.

N. Woodford, D. Livermore, S. Mushtaq, 2021, The Journal of antimicrobial chemotherapy.

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae

N. Woodford, D. Livermore, M. Doumith, 2018, The Journal of antimicrobial chemotherapy.

AmpC &bgr;-lactamase induction by avibactam and relebactam

N. Woodford, D. Livermore, S. Mushtaq, 2017, The Journal of antimicrobial chemotherapy.

Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

D. Livermore, G. Williams, M. Warner, 2010, The Journal of antimicrobial chemotherapy.

Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized β-Lactamases

D. Livermore, S. Mushtaq, Yigong Ge, 2004, Antimicrobial Agents and Chemotherapy.

SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.

D. Livermore, T. Cai, S. Mushtaq, 2022, International journal of antimicrobial agents.

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

N. Woodford, D. Livermore, M. Warner, 2018, The Journal of antimicrobial chemotherapy.

Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.

D. Livermore, M. Warner, S. Mushtaq, 2013, The Journal of antimicrobial chemotherapy.

Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes.

D. Livermore, S. Mushtaq, T. Ida, 2013, The Journal of antimicrobial chemotherapy.

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.

Neil Woodford, N. Woodford, D. Livermore, 2011, International journal of antimicrobial agents.

Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.

N. Woodford, D. Livermore, S. Mushtaq, 2013, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

D. Livermore, M. Warner, S. Mushtaq, 2009, International journal of antimicrobial agents.

Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.

D. Livermore, M. Warner, Alan P. Johnson, 2004, The Journal of antimicrobial chemotherapy.

Inherent colistin resistance in genogroups of the Enterobacter cloacae complex: epidemiological, genetic and biochemical analysis from the BSAC Resistance Surveillance Programme.

M. C. Gilmore, M. Valvano, R. Reynolds, 2020, The Journal of antimicrobial chemotherapy.

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

N Woodford, N. Woodford, D. Livermore, 2011, The Journal of antimicrobial chemotherapy.

Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.

N. Woodford, D. Livermore, S. Mushtaq, 2021, International journal of antimicrobial agents.

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales

N. Woodford, D. Livermore, S. Mushtaq, 2022, Journal of Antimicrobial Chemotherapy.

In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.

A. Charlett, D. Livermore, D. James, 2003, International Journal of Antimicrobial Agents.

Characterization of b -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline 1 avibactam (NXL104)

N. Woodford, D. Livermore, M. Warner, 2012 .

Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.

N. Woodford, D. Livermore, S. Mushtaq, 2022, The Journal of antimicrobial chemotherapy.

Detection of CTX-M-15 extended-spectrum β-lactamase in the United Kingdom

N. Woodford, D. Livermore, S. Mushtaq, 2003 .

Are resistance rates among bloodstream isolates a good proxy for other infections? Analysis from the BSAC Resistance Surveillance Programme.

D. Livermore, R. Reynolds, S. Mushtaq, 2021, The Journal of antimicrobial chemotherapy.

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

N. Woodford, D. Livermore, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.

D. Livermore, M. E. Ward, M. Warner, 2005, Journal of Antimicrobial Chemotherapy.

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases.

N. Woodford, D. Livermore, S. Mushtaq, 2020, The Journal of antimicrobial chemotherapy.

Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.

D. Livermore, M. Warner, S. Mushtaq, 2011, International journal of antimicrobial agents.

Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae

N. Woodford, D. Livermore, A. Haldimann, 2019, The Journal of antimicrobial chemotherapy.

Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.

N. Woodford, D. Livermore, D. James, 2015, The Journal of antimicrobial chemotherapy.

Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters.

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria

J. Nieman, S. Cusack, D. Livermore, 2013, Antimicrobial Agents and Chemotherapy.

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

N. Woodford, D. Livermore, M. Warner, 2009, The Journal of antimicrobial chemotherapy.

Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.

D. Livermore, M. Warner, Alan P. Johnson, 2004, The Journal of antimicrobial chemotherapy.

Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.

D. Livermore, S. Mushtaq, C. Horner, 2020, The Journal of antimicrobial chemotherapy.

Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study

A. Oliver, M. Delmée, D. Livermore, 2017, The Journal of antimicrobial chemotherapy.

In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci

S. North, N. Woodford, D. Livermore, 2007, Antimicrobial Agents and Chemotherapy.

In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.

J. Wain, N. Woodford, D. Livermore, 2014, International journal of antimicrobial agents.

AmpC induction by ceftaroline.

D. Livermore, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014

N. Woodford, D. Livermore, R. Hill, 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms.

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.

D. Livermore, M. Warner, S. Mushtaq, 2001, Journal of Antimicrobial Chemotherapy.

Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria

Y. Barenholz, D. Livermore, S. Mushtaq, 2021, Pharmaceutics.

Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci.

D. Livermore, M. Warner, S. Mushtaq, 2014, International journal of antimicrobial agents.

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

N. Woodford, D. Livermore, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.

D. Livermore, M. Warner, S. Mushtaq, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

N. Woodford, D. Livermore, M. Warner, 2011, The Journal of antimicrobial chemotherapy.

with Activity against Gram-negative Bacteria

J. Nieman, S. Cusack, D. Livermore, 2013 .

Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method.

D. Livermore, D. James, A. Johnson, 2004, The Journal of antimicrobial chemotherapy.

Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

N. Woodford, D. Livermore, M. Doumith, 2017, The Journal of antimicrobial chemotherapy.